
Opinion|Videos|December 5, 2024
Efficacy and Safety of Current Treatments for HS
Panelists discuss how current HS treatments, ranging from topical antibiotics to biologics, show varying degrees of efficacy in managing symptoms, while highlighting the need for individualized treatment approaches based on disease severity and patient factors.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Case Report Highlights Rural Care Gaps in Recurrent Merkel Cell Carcinoma
5













